REGN R&D to Revenue
Regeneron Pharmaceuticals · R&D to Revenue
REGN R&D to Revenue
Latest reported38.03%period ending
REGN Quarterly R&D/Revenue (0.00% → 38.03%)
Latest values, visible window
High-resolution chart · PNG
REGN r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 38.0264% | |
| 45.6371% | |
| 41.8634% | |
| 41.5017% | |
| 38.9515% | |
| 44.2335% | |
| 37.6306% | |
| 35.6841% | |
| 34.5042% | |
| 39.9205% | |
| 30.5914% | |
| 28.8429% | |
| 31.101% | |
| 31.6783% | |
| 27.5773% | |
| 27.883% | |
| 25.196% | |
| 25.9519% | |
| 14.3607% | |
| 17.1513% | |
| 12.5153% | |
| 26.7133% | |
| 28.1811% | |
| 27.2581% | |
| 33.9754% | |
| 28.8699% | |
| 36.6568% | |
| 27.132% | |
| 52.8204% | |
| 31.699% | |
| 28.9678% | |
| 31.3515% | |
| 30.8234% | |
| 30.5811% | |
| 31.1844% | |
| 32.7873% | |
| 32.3001% | |
| 35.5817% | |
| 36.7049% | |
| 42.2259% | |
| 46.1749% | |
| 39.1483% | |
| 42.0016% | |
| 37.4464% | |
| 39.0871% | |
| 39.4559% | |
| 43.8405% | |
| 46.5326% | |
| 44.2393% | |
| 45.9263% | |
| 43.9277% | |
| 37.5268% | |
| 40.9628% | |
| 41.0084% | |
| 43.6621% | |
| 37.0119% | |
| 48.4144% | |
| 59.9088% | |
| 104.931% | |
| 124.3998% | |
| 132.779% | |
| 115.3185% | |
| 93.669% | |
| 115.1577% | |
| 107.4556% | |
| 113.4613% | |
| 122.7169% | |
| 89.7654% | |
| 104.6639% | |
| 109.5558% | |
| 136.6728% | |
| 112.6113% | |
| 109.767% | |
| 108.6675% | |
| 100.1468% | |
| 231.675% | |
| 197.6301% | |
| 261.1794% | |
| 345.7761% | |
| 222.7855% | |
| 178.6167% | |
| 176.1019% | |
| 217.5792% | |
| 253.8965% | |
| 248.3319% | |
| 221.5559% | |
| 73.8777% | |
| 89.8929% | |
| 127.7254% | |
| 51.9132% | |
| 156.3887% | |
| 199.2295% | |
| 320.1386% | |
| 339.2857% | |
| 701.4454% | |
| 522.2967% | |
| 551.3018% | |
| 515.5839% | |
| 683.9355% | |
| 456.9161% |